It has been previously demonstrated that EGFR agonists can induce cardiac hypertrophy and remodeling through the activation of metalloproteinases that cleave and release EGFR ligands (Asakura et al., 2002). The gene discussed is EGFR; the disease is cardiac hypertrophy.